Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
164,371,652
-
Shares change
-
-1,761,792
-
Total reported value, excl. options
-
$460,365,265
-
Value change
-
-$1,917,859
-
Put/Call ratio
-
191%
-
Number of buys
-
66
-
Number of sells
-
72
-
Price
-
$2.80
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2024
As of 30 Sep 2024 Allogene Therapeutics, Inc. - Common Stock (ALLO) had 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 164,371,652 shares of stock of the company.
Largest 10 holders included FMR LLC, TPG GP A, LLC, BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, Capital World Investors, Lynx1 Capital Management LP, PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This table shows 152 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.